Jaguar Mining: Gold Producer in Brazil’s Largest Mining State. If you are interested in www.streetinsider.com content, APIs are available. For more information about Jaguar, please visit https://jaguar.health. Toronto, Ontario M5X 1C9 Office: +1 416.847.1854 In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). First Canadian Place 100 King Street West, 56th Flr. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity. Slavery and Human Trafficking Statement, REGISTERED OFFICE: ABBEY ROAD, WHITLEY, COVENTRY, CV3 4LF. The forward-looking statements in this release are only predictions. NEW LAND ROVER DEFENDER. Novel "targeted cancer therapy" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may activate intestinal chloride ion channel-mediated secretory pathways leading to increased electrolyte and fluid content in the gut lumen, which results in passage of loose/watery stools, i.e. Download Investor day 2018. First Canadian Place 100 King Street West, 56th Flr. Just enter your e-mail address and click Submit. These include statements regarding the development of crofelemer for the potential additional indication of symptomatic relief of CTD, and the expectation that reducing frequency of watery stools in cancer patients will allow better adherence to the therapeutic dosing of any targeted therapies, potentially leading to better clinical outcomes. * In ‘Nepse vs Jaguar’, Jaguar’s returns are marked to market. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived gastrointestinal products on a global basis. Mytesi is not indicated for the treatment of infectious diarrhea. The automotive industry in experiencing unprecedented challenges, with the weak market conditions in China and signs of weaker industry conditions in other markets; geopolitical uncertainty with rising populism, tariff and trade tensions and not to mention Brexit in the UK. Peter Hodge secretory diarrhea. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. Investor Relations. Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Investor Relations The automotive industry in experiencing unprecedented challenges, with the weak market conditions in China and signs of weaker industry conditions in other markets; geopolitical uncertainty with rising populism, tariff and trade tensions and not to mention Brexit in the UK. Jaguar Investor Relations at Jaguar Land Rover; JAGUAR LAND ROVER JOB SEARCH At the moment this job search page is for selected opportunities only (UK, Ireland, Slovakia and Hungary). Pilar Gold Mine March 2016 . Mytesi is not indicated for the treatment of infectious diarrhea. Please contact us here http://www.streetinsider.com/signup_content.php. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. TSX:JAG Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. * In ‘Nepse vs Jaguar’, Jaguar’s returns only indicate the performance of it's stock portfolio. For more information about Jaguar, please visit https://jaguar.health. Certain statements in this press release constitute 'forward-looking statements.' Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million, respectively Company to host investor call Monday, November... | November 16, 2020 The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Motors. Pacheca Geophysics Survey. Sign up to receive e-mail alerts whenever Jaguar Health, Inc. posts new information to the site. In addition, gross sales may not be realized in the form of cash receipts as promotional payments and allowances may be deducted from payments received from certain customers. Peter HodgeJaguar Health, Inc.phodge@jaguar.healthJaguar-JAGX, Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea, Sustainability & Community Benefit Sharing, https://www.accesswire.com/596280/Jaguar-Health-Subsidiary-Napo-Pharmaceuticals-Completes-Filing-of-Investigational-New-Drug-Application-for-Crofelemer-Mytesi-for-Symptomatic-Relief-of-Cancer-TherapyRelated-Diarrhea. Toronto, Ontario M5X 1C9 Office: +1 416.847.1854 Email: ir@jaguarmining.com.br. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). You reached this page when attempting to access https://www.streetinsider.com/Accesswire/Jaguar+Health+to+Host+Investor+Call+Monday%2C+November+16th+at+8%3A30+a.m.+Eastern+Regarding+Q3+2020+Financials+%26+Business+Updates/17582937.html from 66.198.240.31 on 2020-11-18 10:41:03 UTC. JavaScript needs to be enabled to complete CAPTCHA. Jaguar Corporate Video (Portuguese) - February 2017. Rule out infectious etiologies of diarrhea before starting Mytesi. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. For more information about Napo, visit www.napopharma.com. After completing the CAPTCHA below, you will immediately regain access to www.streetinsider.com. Media . We have learned from business development discussions with cancer drug manufacturers that adoption and continued use of targeted cancer therapies is directly related to the ability of patients to tolerate use of the therapies - highlighting the importance of supportive care drugs like Mytesi to help manage cancer treatment-related diarrhea in this patient population.". Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Investor Information Investor Relations Contact. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. A significant proportion of patients undergoing cancer therapy experience diarrhea. Full Story. HRH THE PRINCE OF WALES OFFICIALLY OPENS THE NATIONAL AUTOMOTIVE INNOVATION CENTRE, BESTSELLING EVOQUE AND DISCOVERY SPORT SUVS NOW AVAILABLE AS PLUG-IN HYBRIDS WITH ALL-ELECTRIC RANGE OF UP TO 66KM, JAGUAR LAND ROVER UNVEILS FUTURE OF URBAN MOBILITY, JAGUAR LAND ROVER SCALES UP FACE VISOR PRODUCTION FOR NHS STAFF FIGHTING CORONAVIRUS, TALENTED FEMALE STUDENTS INSPIRED TO FURTHER THEIR FUTURES, JAGUAR LAND ROVER EXPANDS ELECTRIFIED LINE-UP WITH THREE-CYLINDER PLUG-IN HYBRID. Gross sales percentages are based on gross sales figures that represent Mytesi orders placed by wholesalers with Jaguar's third-party logistics warehouse, which generate invoiced sales and cash flow for Napo. Additionally, gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been defined by the Company's internal reporting practices. Search. When: Monday, November 16, 2020 at 8:30 a.m. Eastern Time, Live webcast on the investor relations section of Jaguar's website (click here), Replay of the webcast on the investor relations section of Jaguar's website (click here). As you were browsing www.streetinsider.com something about your browser made us think you were a bot. Jaguar Corporate Video (English) - February 2017. A significant proportion of patients undergoing cancer therapy experience diarrhea. JAGUAR LAND ROVER EXPANDS ELECTRIFIED LINE-UP WITH THREE-CYLINDER PLUG-IN HYBRID. Image. About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. In the third quarter of 2020, the Company's animal product commercialization efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal. Investor Information; News Releases; SEDAR; ESTMA; Financial Reports; Analyst Coverage; Presentations & Media. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP. Crofelemer, the active ingredient in Mytesi, comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Investor News Annual Report Governance Reports and Downloads Financial Calendar. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Electrical Distribution System Lead Design Engineer, Electrical Distribution System Group Leader, Product Manager - Software Defined Networking, Assisted & Automated Driving Test Engineer Radars - D Grade, Assisted & Automated Driving Test Case Engineer - D Grade, Assisted & Automated Driving Test Engineer Low Speed Manoeuvring - C Grade, Assisted & Automated Driving Test Engineer Low Speed Manoeuvring - D Grade, Jaguar Investor Relations at Jaguar Land Rover. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. See full Prescribing Information at Mytesi.com. Search. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. Rule out infectious etiologies of diarrhea before starting Mytesi. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. JLR Investor Relations Presentation September 2018. Investor Relations. About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. For more information about Napo, visit www.napopharma.com. Mytesi gross sales are reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales. Corporate Media Jaguar Media Land Rover Media Twitter. Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million, respectively, Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Sustainability & Community Benefit Sharing, Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results, Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates, Jaguar Health Receives Positive Nasdaq Listing Determination, Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer". … SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc. ("Napo") has completed the filing of the investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for crofelemer (Mytesi®) for the planned indication of prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy ("cancer therapy‑related diarrhea" (CTD)). http://www.streetinsider.com/signup_content.php. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. REGISTERED OFFICE: ABBEY ROAD, WHITLEY, COVENTRY, CV3 4LF. IT DOES ALL ITS OWN STUNTS. Turmalina March 2016. Jaguar Health, Inc.phodge@jaguar.health Live webcast on the investor relations section of Jaguar's website . REGISTERED IN ENGLAND NO: 1672070, Jaguar Land Rover is part of Tata See full Prescribing Information at Mytesi.com. Investor Information Investor Relations Contact. CEO Interview. Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance of Mytesi, salesperson performance, and product growth or declines. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. JAGUAR LAND ROVER AUTOMOTIVE PLC The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts.
2020 jaguar investor relations